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Raynold V Yin and Olivia J Phung*Abstract
Aims: Chromium (Cr) is a trace element involved in glucose homeostasis. We aim to evaluate and quantify the
effects of Cr supplementation on A1C and FPG in patients with T2DM.
Materials and methods: A systematic literature search of Pubmed, EMBASE and the Cochrane Library (from database
inception to 11/2014) with no language restrictions sought RCTs or cohort studies evaluating Cr supplementation
in T2DM vs control and reporting either change in glycated hemoglobin (A1C) or fasting plasma glucose (FPG).
Meta-analysis was conducted on each subtype of Cr supplement separately, and was analyzed by random effects
model to yield the weighted mean differences (WMD) and 95% confidence intervals (CIs). Heterogeneity was
assessed by using the I2 statistic.
Results: A total of 14 RCTs (n = 875 participants, mean age range: 30 to 83 years old, 8 to 24 weeks of follow-up) were
identified (Cr chloride: n = 3 study, Cr picolinate: n = 5 study, brewer’s yeast: n = 4 study and Cr yeast: n = 3 study).
Compared with placebo, Cr yeast, brewer’s yeast and Cr picolinate did not show statistically significant effects on
A1C. Furthermore, compared to control, Cr chloride, Cr yeast and Cr picolinate showed no effect on FPG, however,
brewer’s yeast showed a statistically significant decrease in FPG −19.23 mg/dL (95% CI = −35.30 to −3.16, I2 = 21%,
n = 137).
Conclusions: Cr supplementation with brewer’s yeast may provide marginal benefits in lowering FPG in patients with
T2DM compared to placebo however it did not have any effect on A1C.
Keywords: Chromium, Diabetes mellitus, Fasting plasma glucose, Glycated hemoglobin, Meta-analysis, Systematic reviewIntroduction
Type 2 diabetes mellitus (T2DM) is the most prevalent
form of diabetes worldwide [1,2]. It is characterized by
defects in pancreatic insulin secretion or action causing
hyperglycemia attributable to disturbances in carbo-
hydrate, fat and lipid metabolism [1]. The worldwide
prevalence of T2DM is increasing and more than 366
million people are expected to be affected by the year
2030 [2]. Symptomatic adverse drug events associated
with current therapy may affect the patients’ adherence
and the overall risk-benefit ratio of a drug [3]. Despite
the advances in modern medicine, T2DM continues to
be a public health concern. In a study conducted by the* Correspondence: ophung@westernu.edu
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unless otherwise stated.Medical Expenditure Panel Survey, individuals with dia-
betes are 1.6 times more likely to use alternative medi-
cine, such as chromium, as compared to individuals
without [4,5].
Chromium (Cr) is a common supplement used by
many patients with T2DM for the purpose of improving
glucose regulation and in 2002, sales of chromium sup-
plements were estimated at $85 million [6]. According
to the National Institute of Health: Office of Dietary
Supplements, an adequate intake of Cr for men and
women is 35 and 25 μg/day, resepectively [7,8]. Chro-
mium chloride is the naturally occurring trivalent variety
of chromium found in common food sources such as:
whole grains, broccoli, mushrooms and green beans. In
contrast, Cr picolinate is the synthetic sibling of Cr
chloride. Additional forms of Cr supplementation mayral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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is an essential micronutrient linked to the regulation of
many processes in the human body including glucose
homeostasis. Chromium helps to regulate glucose
homeostasis by activating insulin receptors through the
oligopeptide chromudulin thereby increasing insulin sig-
nal transduction and sensitivity [8]. A deficiency in Cr
may result in glucose intolerance, elevated circulating in-
sulin, fasting hyperglycemia, and even impair growth [9].
In recent years, using Cr for treatment of T2DM has
been called into question because of mixed results from
published data. There is currently insufficient evidence
in the literature to make a definitive conclusion about
the effects of Cr on glucose control. Current trials evalu-
ating Cr supplementation on glucose control has re-
sulted in conflicting results. The aim of this systematic
review and meta-analysis is to assess the effectiveness of
Cr supplementation in lowering A1C and FPG in pa-
tients with T2DM.
Materials and methods
Data source and search strategy
A comprehensive systematic literature search of Pubmed,
Embase, and the Cochrane Library was conducted from
the inception of each database to November 2014 with no
language restrictions applied. The search strategy com-
bined keywords and medical subject headings related toFigure 1 PRISMA diagram. Flowchart depicting when studies were excluCr supplementation and T2DM. A manual search of refe-
rences from relevant articles was also performed to iden-
tify any additional studies. For further details about the
search strategy, see Appendix.
Study selection, data abstraction and validity assessment
Studies were included in the analysis if they were either
RCTs or observational trials in patients with T2DM
evaluating Cr supplementation in any dose or form, and
also reported any of the following endpoints: A1C or
FPG. Two investigators were responsible for completing
study selection, data abstraction and validity assessment
for all trials evaluated in this study. Data abstraction was
completed by each investigator independently using a
standardized data abstraction tool. Each investigator was
responsible for obtaining the following information from
each trial: author, publication year, funding source, de-
scription of study population, inclusion and exclusion
criteria, study design, duration of study and intervention
details. Validity assessment of RCTs was completed
using the Cochrane Risk of Bias Tool [10]. The validity
assessment had six domains covering: randomization,
allocation concealment, blinding, blinding of outcomes
assessment, incomplete data reporting and selective re-
porting. Each domain was scored as either having a low,
unclear, or high risk of bias. Any discrepancies were re-
solved through discussion.ded from the study and why.
Table 1 Baseline study characteristics
Author,
year, N














30-75YO, T2DM ≥4 months,
stable on OHA x3 months,
FBG 140-250 mg/dL, A1C
7.5-12%, BMI 20-35 kg/m2
16 weeks Chromium chloride
(n = 38)
200 mcg, BID 62 ± 53, 58 NR 8.4 ± 8.6, 171 ± 314 NR, 28 ± 26






3 months Chromium picolinate
(n = 25)
400 mcg, unspecified 51 ± 10, 28 NR 7.5 ± 1.6, 129 ± 44 104 ± 32, 37 ± 11
Placebo (n = 25) — 49 ± 10, 8 NR 7.84 ± 1.7, 142 ± 62 100 ± 28, 38 ± 9
Król, 2011,
N = 40





8 weeks Brewer’s yeast (n = 20) 100 mcg, 2 tablets QAM,
2 tablets in the afternoon,
1 tablet QPM
55 ± 9 years old
for N = 40, 55 for
N = 50
11.5 ± 7.8
for N = 40
8.09 ± 2.17, 194 ± 61 NR, 35 ± 9
Placebo (n = 20) — 55 ± 9 years old
for N = 40, 55 for
N = 50
11.5 ± 7.8
for N = 40




authors noted that patients
who enrolled had T2DM
3 months Brewer’s yeast (n = 20) 42 mcg, 3 capsules TID 35-67 years old
for N = 40, NR
NR 9.5 ± 1.2, 198 ± 30 NR, 25 ± 9
Placebo (n = 20) — 35-67 years old
for N = 40, NR
NR 9.30 ± 0.98, 226 ± 82 NR, 26 ± 4
Lai, 2008,
N = 20
<56YO, DM × 5 years,
FBG > 153 mg/dL,
A1C > 8.5%
6 months Chromium yeast (n = 10) 1,000 mcg, unspecified 53 ± 2, 40 NR 10.2 ± 0.5, 225 ± 9 NR, 26 ± 0.9
Placebo (n = 10) — 51 ± 2, 50 NR 10.1 ± 0.4, 221 ± 17 NR, 26 ± 0.8
Kleefstra, 2007,
N = 57
A1C 7–8.5%, only on OHG,
no change to TX in 3
months, CrCl >50 mL/min,
ALT <90 units/L
6 months Chromium yeast (n = 29) 100 mcg, 2 tablets BID 68 ± 8, 62 6 6.9 ± 0.67, 157 ± 41 88 ± 20, 30 ± 6
Placebo (n = 28) — 66 ± 9, 61 4.5 7.01 ± 0.50, 144 ± 32.4 87 ± 17, 30 ± 6
Kleefstra, 2006,
N = 46
<75YO, A1C >8%, daily
insulin ≥50 units,
CrCl >50 mL/min
6 months Chromium picolinate
(n = 14)
250 mcg, BID 60 ± 9, 29 13 ± 5 9.43 ± 1.09, NR NR, 35 ± 7
Chromium picolinate
(n = 15)
500 mcg, BID 59 ± 6, 33 11 ± 6 9.67 ± 0.91, NR NR, 33 ± 4





12 weeks Chromium enriched
yeast (n = 19)
100 mcg, 2 tablets BID 60.8 [37–80], 37 3 7.18 ± 1.52, 148 ± 46 NR, 34 ± 6






3 months Chromium picolinate
(n = 30)
1,000 mcg, unspecified NR, NR NR 6.9 ± 1, 160 ± 36 NR, 30 ± 4
Placebo (n = 30) — NR, NR NR 7.0 ± 1.5, 164 ± 43 NR, 31 ± 5
Ghosh, 2002,
N = 100
T2DM, glycemic control ×3




12 weeks Chromium picolinate
(n = 50)
200 mcg, BID NR, NR NR 7.2 ± 2.5, 124 ± 45 NR, NR
















Table 1 Baseline study characteristics (Continued)
Bahijiri, 2000,
N = 141
T2DM, negative history of
pituitary, thyroid, kidney, or
liver disease, no digestive
problems, no vitamin
supplements
8 months Chromium chloride
(n = 67)
200 mcg, unspecified 36-68 years old
for N = 141, 38
for N = 141
NR NR, NR NR, 31 ± 8
Brewer’s yeast (n = 74) 23.2 mcg, unspecified
Placebo (n = 69) —
Anderson, 1997,
N = 155
Free of other disease, T2DM,
25-65YO, FBG between 130
mg/dL – 230 mg/dL, 2HOGTT
between 170 mg/dL –
300 mg/dL, A1C between
8% – 12%
4 months Chromium picolinate
(n = 53)
100 mcg, BID 56 ± 1, NR 8 ± 1 9.4 ± 2.18, 184 ± 39 69 ± 2, 25 ± 0.5
Chromium picolinate
(n = 52)
500 mcg, BID 55 ± 1, NR 5 ± 0.7 9.4 ± 2.16, 176 ± 39 68 ± 1, 25 ± 0.4
Placebo (n = 50) — 56 ± 1, NR 5 ± 0.7 9.1 ± 2.12, 176 ± 38 69 ± 1, 25 ± 0.5
Abraham, 1992,
N = 25
Authors did not clearly
specify, however, they did
note that patients with T2DM
were enrolled and had
established atherosclerotic
disease
16 months Chromium chloride
(n = 13)
250 mcg, unspecified NR, NR NR NR, 175 ± 36 NR, NR
Placebo (n = 12) — NR, NR NR NR, 176 ± 42 NR, NR
Hunt, 1985,
N = 39
T2DM, BG >140 mg/dL,
A1C >8%
90 days Brewer’s yeast (n = 22) 68 mcg/day, BID 62 ± 16 years old
for N = 39, 73 for
N = 79
NR 11.1, 204 123 ± 22 for N = 39, NR
Placebo – Torula yeast
(n = 17)
— 62 ± 16 years old
for N = 39, 73 for
N = 9
NR 11, 186 123 ± 22 for N = 39, NR
Abbreviations: T2DM type 2 diabetes mellitus, OHA oral hyperglycemic agent, FBG fasting blood glucose, BID twice daily, TID three times daily, QAM daily in the morning, QPM daily in the evening, DM diabetes mellitus,
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To explore and quantify the changes Cr supplementa-
tion has on A1C and FPG, each parameter was treated
as a continuous variable. The weighted mean differences
(WMDs) and accompanying 95% confidence intervals
(CI) were pooled using a DerSimonian and Laird random-
effects model [11]. Meta-analysis was conducted on each
subtype of Cr supplement separately using StatsDirect
software version 2.7.9. A p-value of <0.05 was considered
statistically significant for all analyses. Moreover, statis-
tical heterogeneity between individual trials was deter-
mined using the I2 statistic. Heterogeneity value ranges
from 0 to 100, with 25, 50 and 75% representing low,
moderate, and high risk of statistical heterogeneity, re-
spectively. Publication bias was planned using visual in-
spection of funnel plots to identify the relationship
between effect size and sample size and Egger’s weighted
regression statistic was used to evaluate asymmetry
[12,13]; however, the small number of RCTs per analysis
precluded the ability to statistically analyze this.
Results
Study characteristics
Upon screening for inclusion and exclusion of studies, 14
nonduplicate RCTs (n = 875 patients, mean age range: 30
to 83 years old, 8 to 24 weeks of follow-up) met inclusion
criteria (Figure 1) [13-27]. No observational studies wereFigure 2 Cochrane risk of bias assessment tool. Six domains are evalua
participants and personnel, blind of outcomes assessment, incomplete out
unknown or low risk of bias, respectively.found to be eligible for inclusion in this study. Of the 14
unique studies identified, 11 reported results for A1C and
12 reported results for FPG. Patients in the intervention
group received Cr supplement (dosing range 126 mcg-
1,000 mcg daily) in the form of either: Cr chloride (n = 3)
[17,18,20], Cr picolinate (n = 5) [16,21,23,24,28], Cr yeast
(n = 3) [26,27,29], or brewer’s yeast (n = 4) [15,18,22,25].
Cr was dosed one to three times daily (Table 1). Assess-
ment for the Cochrane Risk of Bias tool is presented in
Figure 2. The Cr levels for patients included in this meta-
analysis were either not reported or within normal limits.
Quantitative data synthesis
For each Cr subtype evaluated, publication bias was
either not detected or unobtainable due to few studies.
Cr chloride
Chromium chloride is the naturally occurring trivalent
variety of chromium found in common food sources
such as: whole grains, broccoli, mushrooms and green
beans. Results from the meta-analysis suggests that Cr
chloride did not have a statistically significant effect on
lowering FPG in patients with T2DM when compared
to placebo −6.74 mg/dL (95% CI = −26.64 to 13.16,
I2 = 31%) (Figure 3). Meta-analysis of Cr chloride on
A1C could not be conducted because only one study re-
ported this outcome [20].ted, random sequence generation, allocation concealment, blinding of
come data and selective reporting. – , ? and + represents either a high,
Chromium Supplementation vs. Placebo – FPG
-60 -30 0 30 60 90
Summary -14.71 (-34.10, 4.69)
Racek, 2006 -22.14 (-50.02, 5.74)
Kleefstra, 2007 3.60 (-15.35, 22.55)
Lai, 2008 -24.84 (-35.26, -14.42)
Chromium Yeast
Summary -19.23 (-35.30, -3.16)
Hunt, 1985 -8.00 (-30.99, 14.99)
Bahijiri, 2000 -32.50 (-53.89, -11.11)
Krol, 2011 -13.42 (-46.10, 19.26)
Brewer's Yeast
Summary -8.49 (-22.02, 5.03)
Anderson, 1997 -18.81 (-32.12, -5.50)
Ghosh, 2002 -16.20 (-35.73, 3.33)
Vrtovec, 2005 1.80 (-17.48, 21.08)
Jain, 2012 14.82 (-17.99, 47.63)
Chromium Picolinate
Summary -6.74 (-26.64, 13.16)
Abraham, 1992 19.08 (-22.87, 61.03)
Bahijiri, 2000 -19.80 (-41.36, 1.76)
Chen, 2013 -2.90 (-29.59, 23.79)
Chromium Chloride
Weighted Mean Difference (95% Confidence Interval))
Figure 3 Forest plot depicting results from each subtype of Cr supplement evaluating the effects of FPG vs. placebo based on year
of publication.
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Cr picolinate is the synthetic salt form of Cr chloride.
Picolinic acid may serve to improve chromium absorp-
tion. Upon meta-analysis, Cr picolinate did not show a
statistically significant improvement for lowering A1C −0.60%
(95% CI = −1.27 to 0.07, I2 = 78%, n = 392) (Figure 4) or
FPG −8.49 mg/dL (95% CI = −22.02 to 5.03, I2 = 48%)
(Figure 3) in patients with T2DM.
Cr yeast
An additional form of Cr supplementation may also
come from Cr yeast. Results from this meta-analysis sug-
gests that Cr yeast did not have a statistically significant
improvement in lowering A1C 0.25% (95% CI = −1.07 to
0.57, I2 = 90%, n = 113) (Figure 4) or FPG −14.71 mg/dL
(95% CI = −34.10 to 4.69, I2 = 70%) (Figure 3).
Brewer’s yeast
Trivalent Cr is considered the biologically active form of
Cr and it was originally discovered in brewer’s yeast [30].Brewer’s yeast did not have a statistically significant
effect on lowering A1C in patients with T2D −0.71%
(95% CI = −2.29 to 0.87, I2 = 87%, n = 99) (Figure 4).
However, brewer’s yeast demonstrated a statistically sig-
nificant decrease in FPG −19.23 mg/dL (95% CI = −35.30
to −3.16, I2 = 21%) (Figure 3) in patients with T2DM
compared to placebo.
Discussion
Results from this study suggest that Cr does not have a
statistically significant effect on A1C when administered
in patients with T2DM. Furthermore, Cr chloride, Cr
yeast or Cr picolinate did not improve FPG in patients
with T2DM. However, brewer’s yeast had a statistically
significant reduction in FPG when compared to placebo.
The limitations of this meta-analysis should be consi-
dered when interpreting these results. The high level of
heterogeneity may be a limiting factor of this study.
Visual inspection of funnel plots indicated the potential
for publication bias and a lack of symmetry to some
Chromium Supplementation vs. Placebo – A1C
-3 -2 -1 0 1 2
Summary -0.25 (-1.07, 0.57)
Racek, 2006 -0.20 (-1.24, 0.84)
Kleefstra, 2007 0.25 (-0.04, 0.54)
Lai, 2008
Chromium Yeast
Summary -0.71 (-2.29, 0.87)
Hunt, 1985 0.40 (-0.89, 1.69)
Sharma, 2011
Krol, 2011 -0.25 (-1.32, 0.82)
Brewer's Yeast
Summary -0.60 (-1.27, 0.07)
Anderson, 1997
Ghosh, 2002 -0.70 (-1.51, 0.11)
Vrtovec, 2005 -0.30 (-1.03, 0.43)
Kleefstra, 2006 -0.10 (-0.59, 0.39)
Chromium Picolinate
Weighted Mean Difference (95% Confidence Interval))
Figure 4 Forest plot depicting results from each subtype of Cr supplement evaluating the effects of A1C vs. placebo based on year of
publication. Note: The squares represent the pooled results of that study in addition to all studies preceding it. Error bars represent 95% CIs and
the diamond represents the overall pooled results. The solid vertical line extending upward from 0 is the null value.
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formulation and duration of the study may have contri-
buted to the high heterogeneity of the study. Although
publication bias could not be statistically assessed; the
comprehensive search strategy employed may have pre-
vented the exclusion of relevant evidence. Furthermore,
the trials included in this meta-analysis only included
published trials.
Many factors may have contributed to the polar results
obtained between Abraham et al. [17] and Bahijiri et al.
[19] when exploring the effects of Cr chloride on FPG
when compared to placebo (Figure 3). Changes in the
standard of care for patients with T2DM between 1992
when Abraham et al. [17] was published and 2000 when
Bahijiri et al. [19] was published may have contributed
to the inconsistent results between the two studies. Fur-
thermore, the patient population studied in Abraham
et al. [17] recruited patients who were at high risk (i.e.
previous myocardial infarction, moderate to severe inter-
mittent claudication) compared to patients recruited by
Bahijiri et al. [19]. Furthermore, Bahijiri et al. [19] only
recruited patients who were either of Saudi origin or
Arabs compared to Abraham et al. [17] who did not
exclusively specify ethnic background as a factor for en-
rollment into the study. Consequently, this may haveintroduced variations (i.e. diet and lifestyle differences)
in the patient population, ultimately contributing to the
polar results between the two studies.
Future research evaluating the effects of Cr supple-
mentation should attempt to identify the subgroup of
patients in which Cr therapy may be beneficial (i.e.
T2DM patients with Cr deficiency). Furthermore, a large
sample size with adequate power and sufficient duration
of therapy may be desired for reliable and trustworthy
results. Finally, future research may consider properly
controlling for concomitant antidiabetic medications to
truly isolate the effect size of Cr supplementation in pa-
tients with T2DM.
Although it has been suggested that Cr supplementation
promotes glucose control, there is insufficient evidence in
the literature to make a definitive conclusion about the ef-
fects of Cr in patients with T2DM. Current trials evalua-
ting Cr on glycemic control has led to conflicting results.
Results from a 3 month randomized single-blinded study
evaluating adults with T2DM (35–67 years old) suggested
that Cr supplementation (42 mcg/daily) significantly re-
duced both A1C (9.51 ± 0.26% to 6.68 ± 0.28%; p < 0.001)
and FPG (197.65 ± 8.68 mg/dL to 103.68 ± 6.64 mg/dL;
p < 0.001) [14]. However, results from a double-blinded
RCT evaluating Cr as adjuvant therapy in patients with
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tween the intervention (Cr 400 mcg/daily) and placebo
group for A1C after 6 month [16]. Moreover, results from
a double-blinded, placebo-controlled cross-over trial eva-
luating 30 patients with T2DM also reported no difference
between control and Cr treated (200 mcg/daily) subjects
in glucose control (A1C, FPG) [29].
In conclusion, Cr supplementation with brewer’s yeast
may provide marginal benefits in lowering FPG in pa-
tients with T2DM compared to placebo control however
Cr supplement as other formulations did not have any
effect on A1C or FPG. Consequently, it would be prema-
ture to recommend Cr supplementation as part of the
standard of care in patients with T2DM. Additional re-
search with large sample sizes and well-designed RCTs
are required to further understand which patient popula-
tion would benefit the most from Cr supplement.Appendix
Search Strategy
PubMed
((“chromium” [Mesh] OR “chromium” [all fields]) AND
(“diabetes mellitus, type 2” [Mesh] OR “ type 2 diabetes”
[all fields] OR “type ii diabetes” [all fields] OR “t2dm” [all
fields] OR “tiidm” [all fields] OR “NIDDM” [all fields] OR
“non insulin dependent diabetes” [all fields] OR “type 2
dm” [all fields]) AND (“humans” [mesh]))
Cochrane library
((“chromium” OR “chromium”) AND (“diabetes melli-
tus, type 2” OR “ type 2 diabetes” OR “type ii diabetes”
OR “t2dm” OR “tiidm” OR “NIDDM” OR “non insulin
dependent diabetes” OR “type 2 dm”) AND (“humans”))
Embase
((‘chromium’/exp OR ‘chromium’:ti,ab) AND (‘diabetes
mellitus, type 2’/exp OR ‘ type 2 diabetes’:ti,ab OR ‘type
ii diabetes’:ti,ab OR ‘t2dm’ :ti,ab OR ‘tiidm’:ti,ab OR
‘NIDDM’:ti,ab OR ‘non insulin dependent diabetes’ :ti,ab
OR ‘type 2 dm’:ti,ab) AND (‘humans’/exp))
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